Mechanism of induction of complement susceptibility of erythrocytes by spider and bacterial sphingomyelinases

Immunology

Volumn 107, Issue 1, 2002, Pages 93-101

  Tambourgi, Denise V ^a   De Sousa Da Silva, Marcelo ^a   Billington, Stephen J ^b   Gonçalves De Andrade, Rute M ^a   Magnoli, Fábio C ^a   Songer, J Glenn ^b   Van Den Berg, Carmen W ^c  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF ARIZONA   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; GLYCOPHORIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; SPHINGOMYELIN PHOSPHODIESTERASE; TOXIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CELL ASSAY; CELL SURFACE; CONTROLLED STUDY; CORYNEBACTERIUM; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; LOXOSCELES INTERMEDIA; MEMBRANE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; REGULATORY MECHANISM; SPIDER;

ANIMALS; ANNEXIN A5; BINDING SITES; COMPLEMENT ACTIVATION; CORYNEBACTERIUM PSEUDOTUBERCULOSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; GLYCOPHORIN; HEMOLYSIS; HUMANS; PHOSPHOLIPASE D; SPHINGOMYELIN PHOSPHODIESTERASE; SPIDER VENOMS; SPIDERS;

EID: 0036381064     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01483.x     Document Type: Article

References (41)

1. Barretto OC, Cardoso JL, De Cillo D. Viscerocutaneous form of loxoscelism and erythrocyte glucose-6-phosphate deficiency. Rev Inst Med Trop Sao Paulo 1985; 27:264 -7.
2. Schenone H, Saavedra T, Rojas A, Villarroel F. Loxoscelism in Chile. Epidemiologic, clinical and experimental studies. Rev Inst Med Trop Sao Paulo 1989; 31:403-15.
3. Ginsburg CM, Weinberg AG. Hemolytic anemia and multi-organ failure associated with localized cutaneous lesion. J Pediatr 1988; 112:496-9.
4. Sezerino UM, Zannin M, Coelho LK. et al. A clinical and epidemiological study of Loxosceles spider envenoming in Santa Catarina. Brazil Trans R Soc Trop Med Hyg 1998; 92:546-8.
5. Gendron BP. Loxosceles reclusa envenomation. Am J Emerg Med 1990; 8:51-4.
6. Futrell J. Loxoscelism. Am J Med Sci 1992; 304:261.
7. Bey TA, Walter FG, Lober W, Schmidt J, Spark R, Schlievert PM. Loxosceles arizonica bite associated with shock. Ann Emerg Med 1997; 30:701-3.
8. Tambourgi DV, Petricevich VL, Magnoli FC, Assaf SL, Jancar S, Dias Da Silva W. Endotoxemic-like shock induced by Loxosceles spider venoms: pathological changes and putative cytokine mediators. Toxicon 1998; 36:391-403.
9. Tambourgi DV, Magnoli FC, Von Eickstedt VR, Benedetti ZC, Petricevich VL, da Silva WD. Incorporation of a 35-kilodalton purified protein from Loxosceles intermedia spider venom transforms human erythrocytes into activators of autologous complement alternative pathway. J Immunol 1995; 155:4459-66.
10. Tambourgi DV, Magnoli FC, van den Berg CW, Morgan BP, de Araujo PS, Alves EW, Da Silva WD. Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and complement-dependent hemolysis. Biochem Biophys Res Commun 1998; 251:366-73.
11. Bernheimer AW, Campbell BJ, Forrester LJ. Comparative toxinology of Loxosceles reclusa and Corynebacterium pseudotuberculosis. Science 1985; 228:590-1.
12. Cuevas WA, Songer JG. Arcanobacterium haemolyticum phospholipase D is genetically and functionally similar to Corynebacterium pseudotuberculosis phospholipase D. Infect Immun 1993; 61:4310-16.
13. van den Bosch H. Intracellular phospholipases A. Biochim Biophys Acta 1980; 604:191-246.
14. Forrester LJ, Barrett JT, Campbell BJ. Red blood cell lysis induced by the venom of the brown recluse spider: the role of sphingomyelinase D. Arch Biochem Biophys 1978; 187:355-65.
15. McNamara PJ, Cuevas WA, Songer JG. Toxic phospholipases D of Corynebacterium pseudotuberculosis, C. ulcerans and Arcanobacterium haemolyticum: cloning and sequence homology. Gene 1995; 156:113-18.
16. McNamara PJ, Bradley GA, Songer JG. Targeted mutagenesis of the phospholipase D gene results in decreased virulence of Corynebacterium pseudotuberculosis. Mol Microbiol 1994; 12:921-30.
17. Hodgson AL, Krywult J, Corner LA, Rothel JS, Radford AJ. Rational attenuation of Corynebacterium pseudotuberculosis: potential cheesy gland vaccine and live delivery vehicle. Infect Immun 1992; 60:2900-5.
18. Tambourgi DV, Morgan BP, de Andrade RM, Magnoli FC, van den Berg CW. Loxosceles intermedia spider envenomation induces activation of an endogenous metalloproteinase, resulting in cleavage of glycophorins from the erythrocyte surface and facilitating complement-mediated lysis. Blood 2000; 95:683-91.
19. Pangburn MK, Muller-Eberhard HJ. Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 1978; 75:2416-20.
20. Fearon DT. Regulation by membrane sialic acid of b1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 1978; 75:1971-5.
21. Hsu TY, Renshaw HW, Livingston CW Jr, Augustine JL, Zink DL, Gauer BB. Corynebacterium pseudotuberculosis exotoxin: fatal hemolytic anemia induced in gnotobiotic neonatal small ruminants by parenteral administration of preparations containing exotoxin. Am J Vet Res 1985; 46:1206-11.
22. Reid ME, Lisowska E, Blanchard D. Coordinator's report: glycophorin/band 3 and associated antigens. Transfus Clin Biol 1997; 4:57-64.
23. Bucherl W. Biology and venoms of the most important South American spiders of the genera Phoneutria, Loxosceles, Lycosa, and Latrodectus. Am Zool 1969; 9:157-9.
24. Gatt S, Dinur T, Barenholz Y. A fluorometric determination of sphingomyelinase by use of fluorescent derivatives of sphingomyelin, and its application to diagnosis of Niemann-Pick disease. Clin Chem 1980; 26:93-6.
25. Abraha A, Morgan BP, Luzio JP. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J 1988; 251:285-92.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
27. Brauch H, Roelcke D, Rother U. Glycophorin A inhibits lysis by the complement attack phase. Immunobiology 1983; 165:115-20.
28. Parker CJ, Soldato CM, Telen MJ. Increased efficiency of binding of nascent C3b to the erythrocytes of chronic cold agglutinin disease. J Clin Invest 1984; 74:1050-62.
29. Tanner MJ. The major integral proteins of the human red cell. Baillieres Clin Haematol 1993; 6:333-56.
30. Okada H, Tanaka H. Species-specific inhibition by glycophorins of complement activation via the alternative pathway. Mol Immunol 1983; 20:1233-6.
31. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89:1121-32.
32. Comis A, Easterbrook-Smith SB. Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine. FEBS Lett 1986; 197:321-7.
33. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146:4234-41.
34. Test ST, Mitsuyoshi J. Activation of the alternative pathway of complement by calcium-loaded erythrocytes resulting from loss of membrane phospholipid asymmetry. J Lab Clin Med 1997; 130:169-82.
35. Liu C, Marshall P, Schreibman I, Vu A, Gai W, Whitlow M. Interaction between terminal complement proteins C5b-7 and anionic phospholipids. Blood 1999; 93:2297-301.
36. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD, Lubin BH. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood 1996; 87:1179-87.
37. Wang RH, Phillips G Jr, Medof ME, Mold C. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest 1993; 92:1326-35.
38. Kraus D, Medof ME, Mold C. Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H. Infect Immun 1998; 66:399-405.
39. Ernst JD. Epitope mapping of annexin I. Antibodies that compete with phospholipids and calcium recognize amino acids 42-99. Biochem J 1993; 289:539-42.
40. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123:741-8.
41. Raynal P, Pollard HB. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994; 1197:63-93.